Fuentes-Cazar
K, Toledano-Serrabona J, Alves F, Sánchez-Torres A, Figueiredo R, Gay-Escoda C, Valmaseda-Castellón
E. Knowledge and attitudes
of undergraduate dental students
at the University of
Barcelona regarding antiresorptive
and antiangiogenic medications:
A cross-sectional study. J Clin Exp Dent.
2024;16(10):e1217-23.
doi:10.4317/jced.62092
https://doi.org/10.4317/jced.62092
_____
References
|
1.
Martin TJ, Seeman E. Bone
remodeling: Its local regulation and the emergence of bone fragility. Best Pract Res Clin Endocrinol Metab. 2008;22:701-22. |
|
|
|
|
|
2.
Capulli M, Paone R, Rucci N. Osteoblast and osteocyte: Games without frontiers. Arch Biochem Biophys. 2014;561:3-12. |
|
|
|
|
|
3.
Clarke B. Normal bone anatomy
and physiology. Clin J Am
Soc Nephrol. 2008;3:131-9 |
|
|
|
|
|
4.
Schilling T, Mueller M, Minne
HW, Ziegler R. Mineral apposition
rate in rat cortical bone: Physiologic differences in different sites of the same tibia. J Bone Miner Res. 1992;7:429-32. |
|
|
|
|
|
5.
Eguia A, Bagan L, Cardona
F. Review and update on drugs related
to the development of osteonecrosis of the jaw. Med Oral Patol Oral y Cir Bucal. 2020;25:71-83. |
|
|
|
|
|
6.
Ruggiero S, Dodson T, Aghaloo T, Carlson E, Ward B, Kademani D. American Association
of Oral and Maxillofacial Surgeons'
Position Paper on Medication-Related Osteonecrosis
of the Jaw-2022 Update, J
Oral Maxillofac Surg.
2022; 80:920-43 |
|
|
|
|
|
7.
Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: Similarities
and differences and their
potential influence on clinical efficacy.
Osteoporos Int. 2008;19:733-59. |
|
|
|
|
|
8.
Boquete-Castro A, Gomez-Moreno G, Calvo-Guirado JL, Aguilar-Salvatierra A, Delgado-Ruiz RA. Denosumab and osteonecrosis of the jaw. A systematic
analysis of events reported in clinical trials. Clin Oral Implants Res. 2016;27:367-75. |
|
|
|
|
|
9.
Nicolatou-Galitis O, Schiodt
M, Mendes RA, Ripamonti
C, Hope S, Drudge-Coates L, et al. Medication-related osteonecrosis
of the jaw: Definition and best practice for prevention, diagnosis, and treatment.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127:117-35. |
|
|
|
|
|
10.
Mander KA, Finnie JW. Tumour angiogenesis, anti-angiogenic therapy and chemotherapeutic resistance. Aust Vet J. 2018;96:371-8. |
|
|
|
|
|
11.
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al.
American association of oral and maxillofacial surgeons position
paper on medication-related osteonecrosis
of the jaw - 2014 update. J Oral Maxillofac Surg. 2014;72:1938-56. |
|
|
|
|
|
12.
Krishnan V, Bryant H,1 MacDougald
O. Regulation of bone mass by Wnt
signaling. J Clin Invest. 2006;116:1202-1209. |
|
|
|
|
|
13.
McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related
osteonecrosis of the jaws: A systematic review. Oral Dis. 2018;24:527-36. |
|
|
|
|
|
14.
Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O. Interventions for managing medication-related osteonecrosis
of the jaw. Cochrane Database Syst Rev.
2017;10:CD012432. |
|
|
|
|
|
15.
Rotman-Pikielny P, Leonenko
M, Barzilai L, Nabriski
D, Twito O, et al. Patients'
knowledge and opinions regarding osteoporosis, osteoporosis treatment,
and oral health care. J
Am Dent Assoc. 2019;150:830-8. |
|
|
|
|
|
16.
López-Jornet P, Camacho-Alonso F, Molina-Miñano F, Gomez-Garcia F. Bisphosphonate-associated osteonecrosis
of the jaw. Knowledge and attitudes of dentists and dental students: A
preliminary study. J Eval Clin Pract.
2010;16:878-82. |
|
|
|
|
|
17.
De Lima PB, Brasil VLM, de Castro JFL, de Moraes
Ramos-Perez FM, Alves FA, et al. Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonate-related osteonecrosis
of the jaw. Support Care Cancer. 2015;23:3421-6. |
|
|
|
|
|
18.
Al-Maweri SA, Alshammari
MN, Alharbi AR, Bahein
AA, Alhajj MN, et al. Knowledge
and opinions of saudi dentists regarding dental treatment of patients undergoing bisphosphonates. Eur J Dent 2020;14:144-151. |
|
|
|
|
|
19.
Alhussain A, Peel S, Dempster L, Clokie C, Azarpazhooh A. Knowledge, practices, and opinions of
Ontario dentists when treating patients receiving bisphosphonates. J
Oral Maxillofac Surg. 2015;73:1095-105. |
|
|
|
|
|
20.
Escobedo M, García-Consuegra L, Junquera S, Olay S,
Ascani G, Junquera L. Medication-related
osteonecrosis of the jaw: A survey of knowledge, attitudes, and practices among dentists in the principality of Asturias (Spain).
J Stomatol Oral Maxillofac
Surg. 2018;119:395-400. |
|
|
|
|
|
21.
von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement:
Guidelines for reporting observational studies. BMJ. 2007;335:806-8. |
|
|
|
|
|
22.
Mirelli C, Marino S, Bovio
A, Pederielli S, Dall'Agnola
C, Gianni AB, Biagi R. Medication-related
osteonecrosis of the jaw in dental practice: A retrospective analysis of data from the milan
cohort. Dent J (Basel). 2022;19;89. |
|
|
|
|
|
23.
Heimes D, Mark NA, Kuchen
R, Pabst A, Becker P, Kyyak
S, Thiem DGE, Schulze R, Kämmerer PW. Evaluation of medication-related osteonecrosis
of the jaw (MRONJ) in terms of staging and treatment strategies by dental students at different educational levels. Medicina (Kaunas). 2023;28:252. |
|
|
|
|
|
24.
Bival S, Šimović L, Blažun A, Bergman L, Vražić D, Granić M. Dentists' awareness of medication-related
osteonecrosis of the jaw (risk factors,
drugs, and prevention) in
the republic of croatia. Acta Stomatol Croat. 2023;57:121-32. |
|
|
|
|
|
25.
Zhao N, Li QX, Wang YF, et al. Anti-angiogenic drug aggravates the degree of anti-resorptive drug-based medication-related osteonecrosis of the jaw by impairing
the proliferation and migration function of gingival fibroblasts. BMC Oral Health. 2023;23:330. |
|